All In Biotech

Drug Trial Radar · NCT06693765

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

A Single Dose, Non-randomised, Open-label, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Nov 18, 2024

Primary completion

Apr 23, 2025

Study completion Apr 23, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to investigate the pharmacokinetics, safety, and tolerability of AZD4144 in participants with severe renal impairment, end-stage kidney disease, and in healthy participants.

Conditions

  • Renal Impairment
  • End-stage Kidney Disease
  • Healthy Participants

Interventions

  • AZD4144Drug

    AZD4144 will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observed maximum plasma concentration (Cmax)Time frame: From Day 1 to Day 14
  2. Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf)Time frame: From Day 1 to Day 14
  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast)Time frame: From Day 1 to Day 14
  4. Apparent total body clearance (CL/F)Time frame: From Day 1 to Day 14
  5. Non-renal clearance of drug from plasma (CLNR/F)Time frame: From Day 1 to Day 14
  6. Apparent volume of distribution based on the terminal phase (Vz/F)Time frame: From Day 1 to Day 14
  7. Terminal elimination half-life (t½λz)Time frame: From Day 1 to Day 14
  8. Renal clearance of drug from plasma (CLR)Time frame: From Day 1 to Day 4
  9. Amount excreted (Ae)Time frame: From Day 1 to Day 4
  10. Percentage of dose excreted unchanged in urine (fe)Time frame: From Day 1 to Day 4
  11. Number of Treatment Emergent Adverse Events (TEAEs)Time frame: From Day 1 to Follow-up (Day 14/28)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Bucharest, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.